What is it about?
A majority of metal-based anticancer drugs (e.g. cisplatin) are intravenously administered to patients. Since many of the approved drugs display severe toxic side effects, there is an urgent need to discover more selective metal-based drugs that are associated with less side-effects. Many novel cytotoxic metal-complexes (low IC50) are reported in the literature every year, but very few are advanced to pre-clinical studies. Once reason for this undesirable situation is the fact that little is known about the stability of novel metal-complexes in the bloodstream. In other words it is unclear if the intact drug will be able to reach the intended target tissue.
Featured Image
Why is it important?
We have developed an analytical method that allows to investigate the stability of metal-complexes in human plasma in vitro. The application of this method to investigate novel metal-complexes allows one to investigate if the intact metal-complex has a reasonable chance to reach the cancer tissue in vivo.
Perspectives
The application of the developed analytical method has considerable potential to accelerate more metal-complexes to pre-clinical and clinical studies in order to bring more metal-based drugs to the market.
Dr Juergen Gailer
University of Calgary
Read the Original
This page is a summary of: Application of a Novel Metallomics Tool to Probe the Fate of Metal-Based Anticancer Drugs in Blood Plasma: Potential, Challenges and Prospects, Current Topics in Medicinal Chemistry, January 2021, Bentham Science Publishers,
DOI: 10.2174/1568026620666200628023540.
You can read the full text:
Contributors
The following have contributed to this page
